Schrödinger Closes $85 Million Financing to Advance Computational Platform and Expand Drug Discovery Pipeline

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Schr¶dinger, a privately held company revolutionizing drug discovery through advanced molecular simulations, today announced the closing of an $85 million financing to support continued growth and innovation of its computational platform and expansion of its drug discovery pipeline.

The Bill and Melinda Gates Foundation Trust and WuXi AppTecs Corporate Venture Fund co-led the round, joined by leading life science and tech investors Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures).

Schr¶dinger has demonstrated that precise molecular design can significantly accelerate drug discovery and lead to unexpected solutions that stand to benefit patients. Were pleased to support this exciting stage in Schr¶dingers growth, said Bill Gates, who has led three previous investments in Schr¶dinger since 2010.

The new investment will support Schr¶dingers ongoing research and development to extend the capabilities of its widely adopted computational platform for drug discovery and materials research. The company also plans to add scientists and developers and expand its drug discovery team to work on a growing pipeline of assets. Schr¶dingers pipeline spans both partnered and proprietary programs for a range of indications, including several compounds in clinical development.

We continue to be impressed by Schr¶dingers ability to drive in an innovative way the development of new medicines, said Dr. Ge Li, Chairman of WuXi Group and CEO of WuXi AppTec. We look forward to the accelerated progress this investment will bring for patients who are counting on our industry to deliver medicines and treatments for critical, unmet medical needs.

The investment will allow us to continue to advance our technology platform to help our users accelerate their work in life sciences and materials design. We are also excited to expand our drug discovery efforts, leveraging our platform to grow our pipeline and discover new medicines more efficiently, said Ramy Farid, Ph.D., Schr¶dingers CEO. Our growth will help us realize our mission to improve human health and quality of life.

About Schr¶dinger

Schr¶dinger is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Schr¶dinger has a growing pipeline of early-stage assets and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. In addition, the company has deep partnerships and collaborations in such fields as biotechnology, pharmaceuticals, chemicals, and electronics. Through significant long-term investments in basic research, Schr¶dinger has made scientific breakthroughs across many areas of drug discovery and materials science. Founded in 1990, Schr¶dinger has nearly 400 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrodinger.com.

Stephanie Simon
[email protected]
617-581-9333